[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"early-lung-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:early-lung-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,75,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100624153","evaluation-of-the-effectiveness-of-managing-chemotherapy-side-effects-using-epro-and-a-standardized-telenursing-program-for-cancer-patients-100624153",false,"NCT07405931","Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* Diagnosed with early or advanced gastric, lung, breast, or colon cancer\n* Starting first-cycle chemotherapy with a new anticancer agent\n* Able to use a smartphone without difficulty\n* Willing to provide informed consent to participate in the study\n\nExclusion Criteria:\n\n* Individuals who have difficulty communicating due to cognitive impairment, visual impairment, hearing impairment, or other reasons\n* Individuals who cannot read, write, or understand Korean\n* Other individuals deemed inappropriate for participation by the investigators","ALL","19 Years",{"count":18,"type":19},414,"ESTIMATED","INTERVENTIONAL",[22],"NA","This is a multicenter randomized controlled clinical trial designed to evaluate the clinical efficacy and cost-effectiveness of a digital health platform that integrates a symptom reporting and management software with a standardized telenursing program, allowing cancer patients to actively monitor, report, and self-manage chemotherapy-related adverse effects.",[25,26,27,28,29,30,31,32],"Early Gastric Cancer","Advanced Gastric Cancer","Early Lung Cancer","Advanced Lung Cancer","Early Breast Cancer","Advanced Breast Cancer","Early Colon Cancer","Advanced Colon Cancer","RECRUITING","2026-02-08",{"date":36,"type":37},"2026-02-12","ACTUAL",{"date":39,"type":37},"2025-07-09",{"date":41,"type":19},"2026-09",{"name":43,"class":44},"Ulsan University Hospital","OTHER",5,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":20,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100597929","phase-2-serplulimab-combined-with-cryoablation-for-early-stage-non-small-cell-lung-cancer-100597929","NCT07064876","Serplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung Cancer","A Single-Arm, Phase II Clinical Study of Serplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Participants must meet all of the following criteria to be eligible for the study:\n\nVoluntarily agree to participate in this clinical study. Male or female patients aged ≥18 years at the time of signing the informed consent form (ICF).\n\nHistologically or cytologically confirmed diagnosis of T1N0M0 non-small cell lung cancer (NSCLC) during the cryoablation procedure, classified as stage Ia (tumor size \\>1 cm and ≤3 cm) according to the 9th edition of the AJCC TNM staging system; patients with ground-glass nodules (GGNs) are excluded.\n\nNo detectable driver mutations in EGFR, ALK, or ROS1 genes. Deemed ineligible for or unwilling to undergo surgery or radiotherapy after multidisciplinary team (MDT) discussion.\n\nAt least one measurable target lesion within 4 weeks before the first dose, evaluated by the investigator according to mRECIST (2019) criteria.\n\nEastern Cooperative Oncology Group (ECOG) performance status score of 0 or 2. Life expectancy of ≥12 weeks.\n\nAdequate organ function based on laboratory assessments within 14 days before first dose of study treatment, without prior transfusion, albumin, thrombopoietin, or colony-stimulating factor (CSF) support:\n\nHematologic Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL Platelet count ≥ 75 × 10⁹\u002FL Hemoglobin ≥ 90 g\u002FL Liver function Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN) ALT ≤ 5 × ULN AST ≤ 5 × ULN Albumin ≥ 30 g\u002FL Renal function Serum creatinine ≤ 1.5 × ULN; if \\>1.5 × ULN, creatinine clearance ≥ 50 mL\u002Fmin (calculated by Cockcroft-Gault formula) Coagulation APTT ≤ 1.5 × ULN PT ≤ 1.5 × ULN INR ≤ 1.5 × ULN Urinalysis Urine protein dipstick ≤ 1+; if ≥ 2+, 24-hour urine protein \\\u003C 1 g is acceptable Female participants must have a negative serum pregnancy test within 14 days prior to study treatment and agree to use effective contraception during the study and for at least 6 months after the last dose. Breastfeeding is not permitted during the study.\n\nMale participants must agree to use effective contraception or abstain from heterosexual intercourse during the study and for at least 6 months after the last dose. If the male participant has a female partner of childbearing potential or a pregnant partner, he must use condoms to avoid drug exposure to the embryo. Periodic abstinence and withdrawal are not acceptable contraception methods.\n\nExclusion Criteria:\n\n* Known history of severe hypersensitivity to any monoclonal antibody (Grade \\>3, per NCI-CTCAE v5.0).\n\nPrior treatment with any immune checkpoint inhibitors, such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies.\n\nKnown contraindications to cryoablation. Active infection requiring systemic antimicrobial therapy within 14 days prior to the first dose.\n\nHistory of myocardial infarction within 6 months before first dose, uncontrolled arrhythmias (including QTc ≥450 ms for males or ≥470 ms for females, calculated by Fridericia formula), NYHA Class III or IV heart failure, left ventricular ejection fraction \\\u003C50%, or clinically significant pleural, pericardial, or peritoneal effusion requiring intervention.\n\nUncontrolled or symptomatic hypercalcemia (ionized calcium \\>1.5 mmol\u002FL, or total serum calcium \\>12 mg\u002FdL, or corrected calcium \\>ULN).\n\nHistory or presence of interstitial lung disease, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, or other significant pulmonary conditions that may interfere with evaluation or management of potential treatment-related lung toxicity, as judged by the investigator.\n\nPositive for HBsAg and detectable HBV DNA (active hepatitis B); or positive for HCV antibody and detectable HCV RNA (active hepatitis C); or positive syphilis serology (except non-active infections with specific antibody positive and non-specific antibody negative); or known HIV infection.\n\nActive or suspected autoimmune disease. Patients with stable autoimmune disease not requiring systemic immunosuppressive treatment are allowed.\n\nActive malignancy within 5 years, except for curatively treated localized tumors such as basal cell carcinoma, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the cervix, prostate, or breast with ≥5 years disease-free interval.\n\nReceipt of live or attenuated vaccines within 28 days before the first dose or planned during the study. Inactivated seasonal influenza vaccines are allowed.\n\nReceipt of radical radiotherapy within 3 months before the first dose. Presence of spinal cord compression not controlled by surgery and\u002For radiotherapy.\n\nHistory of deep vein thrombosis (DVT), ongoing anticoagulant or antiplatelet therapy, or history of severe bleeding or DVT associated with anti-angiogenic therapy.\n\nPoorly controlled hypertension, defined as blood pressure ≥160\u002F100 mmHg despite optimal medical therapy.\n\nUnderwent major surgery within 28 days prior to the first dose (major surgery is defined as a procedure requiring at least 3 weeks of recovery before study treatment).\n\nParticipation in another interventional clinical trial within 3 months or 5 half-lives (whichever is longer) before screening.\n\nPlanned or prior organ or bone marrow transplantation. Known history of psychiatric or substance abuse disorders that may interfere with study compliance or assessments.\n\nAny other condition that, in the opinion of the investigator, would make the patient unsuitable for participation in the study.","18 Years",{"count":55,"type":19},25,[57],"PHASE2","The goal of this clinical trial is to learn if serplulimab combined with cryoablation can effectively treat early-stage non-small cell lung cancer (NSCLC) in adults who are not eligible for or decline surgery or radiotherapy. The main questions it aims to answer are:\n\nWhat is the objective response rate (ORR) after combination treatment with serplulimab and cryoablation? What are the progression-free survival (PFS), overall survival (OS), 1-year OS rate, and safety outcomes? This is a single-arm, phase II study with no comparison group.\n\nParticipants will:\n\nReceive cryoablation under CT guidance to locally ablate the tumor Receive intravenous serplulimab (300 mg every 3 weeks) for up to 6 cycles Undergo regular imaging and laboratory tests to assess response and monitor safety Provide blood and tissue samples for optional biomarker research The study will enroll 25 patients with stage Ia NSCLC (tumor size \\>1 cm and ≤3 cm, no ground-glass opacity, EGFR\u002FALK\u002FROS1 wild-type) and aims to explore the potential of combining local and systemic immunotherapy in non-surgical candidates.",[27],[61,62,63],"Cryoablation","early lung cancer","immunotherapy","NOT_YET_RECRUITING","2025-09-08",{"date":67,"type":37},"2025-09-15",{"date":69,"type":19},"2025-10",{"date":71,"type":19},"2027-09",{"name":73,"class":44},"Xi Junjie",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":83,"minAge":53,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":20,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":74},"100208691","chronic-toxicities-related-to-treatment-in-patients-with-localized-cancer-100208691","NCT01993498","Chronic Toxicities Related to Treatment in Patients With Localized Cancer","A Prospective Cohort to Investigate Survivorship Issues in Patients With Early Cancer","CANTO","CANTO - Breast\n\nInclusion Criteria:\n\n* Women,\n* Aged 18 years and over,\n* With an invasive breast cancer diagnosed by cytology or histology,\n* No clinical evidence of metastasis at the time of inclusion,\n* Untreated including scored for breast cancer surgery in progress,\n* Patient receiving a social security system,\n* Patient mastering the French language,\n* Free and informed consent for additional biological samples, different questionnaires and collecting information on resource usage.\n* (Since february 2022) Patient :\n\n  1. Age \\\u003C 45 years at diagnostic\n  2. Or CT2-3, cN0-3, HER2+(RH+or RH-) or RH-HER2-\n  3. Or Eligible to Pembrozilumab, Olaparib, TDM1, Abemaciclib or Ribociclib\n\nExclusion Criteria:\n\n* Metastatic breast cancer,\n* Local recurrence of breast cancer,\n* History of cancer within 5 years prior to entry into the trial other than basal cell skin or carcinoma in situ of the cervix,\n* Already received treatment for breast cancer ongoing,\n* Blood transfusion performed for less than six months,\n* Persons deprived of liberty or under supervision (including guardianship).\n\nCANTO - Lung\n\nInclusion Criteria:\n\n* Aged 18 years and over, Having lung cancer diagnosed by cytology or histology or suspected cancer of the lung,\n* Tumor cTX to cT4, cN0-3,\n* No clinical evidence of metastasis at the time of inclusion (patients with metastases on extension assessment within 6 months following diagnosis will be removed from the study),\n* Eligible for curative treatment by surgery or radiotherapy \\* (note patients treated with exclusive chemotherapy, exclusive radiotherapy or exclusive stereotactic radiotherapy will be out of study)\n* Lack of treatment received for current lung cancer, including surgical treatment\n* Patient benefiting from a social protection scheme,\n* Patient mastering the French language,\n* Free and informed consent for additional biological samples, the different questionnaires and the collection of information on resource consumption.\n\nExclusion Criteria:\n\n* Metastatic lung cancer,\n* Local relapse of lung cancer,\n* History of cancer within 3 years prior to study entry other than basal cell cutaneous or epithelioma in situ of the cervix,\n* Treatment already received for current lung cancer,\n* Blood transfusion carried out less than 6 months ago,\n* Persons deprived of liberty or under guardianship (including curatorship).","FEMALE",{"count":85,"type":19},14750,[22],"The aims of the cohort will be to quantify impact of cancer treatments toxicities , and to generate predictors of chronic toxicity in patients with non-metastatic cancer. Study of the original cohort will be focused on localized breast cancer patients, other localisation in non-metastatic setting will be explored furtherwise, fist of all in lung cancer.\n\nThe project will include four specific aims :\n\n1. To develop a database of chronic treatment related toxicity in a cohort of 14750 women with stage I-III breast cancer (= non metastatic), whatever these treatments are (surgery; radiation therapy; chemotherapy …)\n2. To describe incidence, clinical presentation, and outcome of chronic toxicities.\n3. To describe the psychological, the social and the economic impacts of chronic toxicities.\n4. To generate predictors for chronic toxicities in order to prevent them, based upon biological criteria.\n\nThe expected impact of these toxicities, when identified, will be to improve quality of life and to decrease health cost, by the early identification of patients at high risk of toxicity. Such early identification could lead to prevent toxic effect by: a. developing prevention strategies, b. substituting toxic treatment by a non (less) toxic one.\n\nAlso, such cohort will offer a quantification of the impact of treatment toxicity, that could be further used to quantify medical usefulness of strategies that aim at decreasing treatment toxicities (implementation of predictive biomarker for resistance, cytotoxic-free regimen etc…)",[89,27],"Breast Cancer Nos Metastatic Recurrent",[91,92,93,62],"cancer toxicities","cohort","breast cancer","2024-10-16",{"date":96,"type":37},"2024-10-18",{"date":98,"type":37},"2012-02-20",{"date":100,"type":19},"2034-03",{"name":102,"class":44},"UNICANCER",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":20,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":74},"100500930","single-ultra-high-dose-stereotactic-body-radiation-therapy-for-early-lung-cancer-100500930","NCT05802654","Single Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer","Clinical Study of Single Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer","USBRT-1","Inclusion Criteria:\n\n1. Signed written informed consent;\n2. Male or female aged ≥ 18 years and ≤ 75 years;\n3. patients with early stage lung cancer confirmed by pathology or clinical MDT;\n4. The physical state score (ECOG PS) of the eastern tumor cooperative group was 0 \\~ 1;\n5. Expected survival time ≥3 months;\n6. Laboratory results during screening must meet the following requirements:\n\n   1. Blood routine: neutrophil absolute count (ANC) ≥ 1.5 × 109\u002FL, platelet count (PLT) ≥ 100 × 109\u002FL, hemoglobin (HGB) ≥ 90 g\u002FL (no blood transfusion or erythropoietin dependence within 7 days);\n   2. Liver function: total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal value (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were less than 2.5 times ULN in subjects without liver metastasis, and ALT and AST were less than 5 times ULN in subjects with liver metastasis.\n   3. Renal function: serum creatinine (Cr) ≤1.5 times ULN or Cr clearance ≥60 mL\u002Fmin (Cockcroft-Gault formula), and urine protein (UPRO) \\&lt on routine urine test; 2+ or 24 h urinary protein quantification \\< 1g;\n   4. International standardized ratio (INR) ≤1.5 times ULN and partial prothrombin time (PTT) or activated partial thrombin time (APTT) ≤1.5 times ULN during the 7 days prior to treatment;\n7. For female subjects of reproductive age, urine or serum pregnancy tests should be negative within 3 days prior to receiving the first fraction of SBRT. If the urine pregnancy test results cannot be confirmed negative, a blood pregnancy test is requested;\n8. Compliance with the research protocol is expected to be good.\n\nExclusion Criteria:\n\n1. currently participating in an interventional clinical trial;\n2. any unstable systemic disease, including but not limited to active infection, congestive heart failure \\[New York Heart Association (NYHA) class ≥ II\\], severe arrhythmia requiring medical therapy, liver, kidney, or metabolic disease; Type I and type II respiratory failure;\n3. other malignancies within 5 years before randomization, except adequately treated cervical carcinoma in situ, basal cell or squamous skin cancer, local prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery, or papillary thyroid cancer;\n4. women who are pregnant or breastfeeding or who plan to become pregnant or breastfeeding during the study period;","80 Years",{"count":113,"type":19},100,[22],"The goal of this prospective single-arm phase II study is to study the efficacy and safety of stereotactic body radiotherapy (SBRT) for early lung cancer. The main questions it aims to answer are:\n\nHow effective is this regimen of SBRT for early lung cancer? How safe is this regimen of SBRT for early lung cancer?",[27,117],"Stereotactic Body Radiotherapy",[119,120,121,122],"lung cancer","Stereotactic body radiotherapy (SBRT)","High dose","Fraction","2023-06-20",{"date":125,"type":37},"2023-06-22",{"date":127,"type":19},"2023-06",{"date":129,"type":19},"2028-06",{"name":131,"class":44},"Peking University Third Hospital"]